This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Antifungal Locks to Treat Fungal-related Central Line Infections

This study has been completed.
Astellas Pharma Inc
Information provided by (Responsible Party):
Bill McGhee, University of Pittsburgh Identifier:
First received: July 2, 2009
Last updated: January 12, 2016
Last verified: January 2016

The purpose of this study is to evaluate the usefulness of antifungal lock therapy with liposomal amphotericin B (Ambisome), in combination with systemic antifungal(s), in patients with catheter-related blood stream infections with fungal organisms, whose catheter has not been removed because of the continuing critical need for central line access. The primary group of potential patients will be those with intestinal insufficiency, including post-op small bowel transplant recipients.

The recommendation of the Infectious Disease Society of America (IDSA) is to remove all catheters with fungal infections and treat systemically for 14 days after the last positive culture. However, in certain intestinal failure patients, removal of an infected line might significantly reduce or eliminate intravenous (IV) access and create a life threatening situation. Thus, the investigators' aim is to determine the usefulness of antifungal lock therapy in intestinal failure patients whose catheter has not been removed. The investigators' hope is to salvage central line catheters rather than to remove them.

Condition Intervention Phase
Central Line Fungal Infections Drug: amphotericin B liposomal (Ambisome) Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients

Resource links provided by NLM:

Further study details as provided by Bill McGhee, University of Pittsburgh:

Primary Outcome Measures:
  • The success of antifungal lock therapy (the primary endpoint) will be determined by whether or not the patient has at least 2 negative fungal cultures and the CVC was not removed. [ Time Frame: 5 days of antifungal lock treatment ]

Secondary Outcome Measures:
  • The number of days before the infected central line culture becomes negative [ Time Frame: 5 days of antifungal lock treatment ]
  • The development of fungal-related complications [ Time Frame: Usually 14-28 days ]
  • Test of cure catheter cultures on day 5 and day 30 post antifungal lock [ Time Frame: 45-55 days ]

Enrollment: 13
Study Start Date: September 2006
Study Completion Date: September 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Antifungal lock-treated patients
Intestinal failure and other patients with poor IV access and central line fungal-related infections
Drug: amphotericin B liposomal (Ambisome)
After enrollment, antifungal therapy will be instituted consisting of both IV systemic and antifungal lock therapy. Systemic therapy will be Ambisome administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing up to 2.3 ml of concentrated Ambisome (2 mg/ml) into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days.
Other Name: Ambisome

  Show Detailed Description


Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with intestinal insufficiency and central venous access.
  • Culture positive fungal-related CRBSI.
  • Females of childbearing potential will be eligible for the study.
  • Ambisome carries a category B Pregnancy Risk Factor. Since this is a minimal pregnancy risk category, no special precautions will be taken to determine that the patient is not pregnant.
  • HIV serostatus will not be determined for the purpose of participating in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00936910

United States, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15201
Sponsors and Collaborators
University of Pittsburgh
Astellas Pharma Inc
Principal Investigator: Bill McGhee, PharmD Children's Hospital of Pittsburgh of UPMC
  More Information


Responsible Party: Bill McGhee, Clinical Pharmacy Specialist - Transplantaton, University of Pittsburgh Identifier: NCT00936910     History of Changes
Other Study ID Numbers: Ambisome Locks at CHP
Study First Received: July 2, 2009
Last Updated: January 12, 2016

Keywords provided by Bill McGhee, University of Pittsburgh:
central line fungal infections
antifungal lock therapy
Ambisome lock therapy

Additional relevant MeSH terms:
Communicable Diseases
Amphotericin B
Liposomal amphotericin B
Antifungal Agents
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP3A Inhibitors processed this record on September 21, 2017